[{"address1": "427 Park Street", "city": "Charlottesville", "state": "VA", "zip": "22902", "country": "United States", "phone": "434 297 1000", "website": "https://acumenpharm.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.", "fullTimeEmployees": 51, "companyOfficers": [{"maxAge": 1, "name": "Mr. Daniel J. O'Connell M.B.A.", "age": 54, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 1043294, "exercisedValue": 0, "unexercisedValue": 3599341}, {"maxAge": 1, "name": "Mr. Matt  Zuga", "title": "CFO & Chief Business Officer", "fiscalYear": 2023, "totalPay": 702601, "exercisedValue": 0, "unexercisedValue": 884506}, {"maxAge": 1, "name": "Mr. Derek M. Meisner Esq., J.D.", "age": 53, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 752945, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James  Doherty Ph.D.", "age": 56, "title": "President & Chief Development Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Grant A. Krafft Ph.D.", "title": "Co-Founder", "fiscalYear": 2023, "totalPay": 42000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Caleb E. Finch Ph.D.", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William L. Klein Ph.D.", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Russell  Barton M.S.", "age": 66, "title": "Chief Operating Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 223680, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kelly  Carranza", "title": "Vice President, Finance & Accounting and Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alex  Braun M.B.A.", "title": "VP & Head of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.47, "open": 1.45, "dayLow": 1.39, "dayHigh": 1.49, "regularMarketPreviousClose": 1.47, "regularMarketOpen": 1.45, "regularMarketDayLow": 1.39, "regularMarketDayHigh": 1.49, "beta": 0.039, "forwardPE": -0.91652423, "volume": 338486, "regularMarketVolume": 338486, "averageVolume": 316155, "averageVolume10days": 210510, "averageDailyVolume10Day": 210510, "bid": 1.37, "ask": 1.44, "bidSize": 100, "askSize": 100, "marketCap": 84111720, "fiftyTwoWeekLow": 1.39, "fiftyTwoWeekHigh": 5.09, "fiftyDayAverage": 1.858, "twoHundredDayAverage": 2.562275, "currency": "USD", "enterpriseValue": -82037728, "floatShares": 32417847, "sharesOutstanding": 60079800, "sharesShort": 1829373, "sharesShortPriorMonth": 1426863, "sharesShortPreviousMonthDate": 1734048000, "dateShortInterest": 1736899200, "sharesPercentSharesOut": 0.0304, "heldPercentInsiders": 0.11236, "heldPercentInstitutions": 0.78424, "shortRatio": 4.48, "shortPercentOfFloat": 0.040900003, "impliedSharesOutstanding": 60079800, "bookValue": 3.615, "priceToBook": 0.38727525, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -81672000, "trailingEps": -1.38, "forwardEps": -1.53, "enterpriseToEbitda": 0.884, "52WeekChange": -0.5462963, "SandP52WeekChange": 0.21027291, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ABOS", "underlyingSymbol": "ABOS", "shortName": "Acumen Pharmaceuticals, Inc.", "longName": "Acumen Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1625146200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "0207450b-6c32-3240-a7c9-bbf75fc2138c", "messageBoardId": "finmb_8539521", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.4, "targetHighPrice": 15.0, "targetLowPrice": 6.0, "targetMeanPrice": 10.8, "targetMedianPrice": 11.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 200343008, "totalCashPerShare": 3.335, "ebitda": -92838000, "totalDebt": 29988000, "quickRatio": 10.06, "currentRatio": 10.426, "debtToEquity": 13.807, "returnOnAssets": -0.20987, "returnOnEquity": -0.32834998, "grossProfits": -72522000, "freeCashflow": -41690752, "operatingCashflow": -67314000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]